Alosetron

Drug Profile

Alosetron

Alternative Names: GR-68755; GR-68755C; Lotronex

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Carbolines; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Irritable bowel syndrome
  • Discontinued Anxiety disorders; Cognition disorders; Non-ulcer dyspepsia; Schizophrenia

Most Recent Events

  • 31 Jul 2011 Prometheus Laboratories has been acquired by Nestle
  • 30 Nov 2007 Discontinued - Phase-II for Irritable bowel syndrome in Japan (PO)
  • 07 Nov 2007 Alosetron licensed to Prometheus Laboratories in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top